Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

Arcadia Biosciences (RKDA) EBIAT (2016 - 2025)

Arcadia Biosciences' EBIAT history spans 12 years, with the latest figure at -$1.3 million for Q4 2025.

  • For Q4 2025, EBIAT rose 80.23% year-over-year to -$1.3 million; the TTM value through Dec 2025 reached -$2.3 million, up 72.52%, while the annual FY2025 figure was -$2.3 million, 66.77% up from the prior year.
  • EBIAT reached -$1.3 million in Q4 2025 per RKDA's latest filing, down from $856000.0 in the prior quarter.
  • In the past five years, EBIAT ranged from a high of $144.0 million in Q2 2021 to a low of -$9.4 million in Q1 2023.
  • Average EBIAT over 5 years is $4.8 million, with a median of -$2.5 million recorded in 2023.
  • Peak YoY movement for EBIAT: surged 1555.57% in 2021, then plummeted 374.24% in 2022.
  • A 5-year view of EBIAT shows it stood at -$7.5 million in 2021, then soared by 43.41% to -$4.2 million in 2022, then surged by 32.89% to -$2.8 million in 2023, then plummeted by 137.29% to -$6.8 million in 2024, then surged by 80.23% to -$1.3 million in 2025.
  • Per Business Quant, the three most recent readings for RKDA's EBIAT are -$1.3 million (Q4 2025), $856000.0 (Q3 2025), and -$4.5 million (Q2 2025).